Laboratoire XO

Laboratoire XO (also known as LXO Group) is a French specialty pharmaceutical company founded in 2015 and headquartered in Saint-Cloud, France. The company specializes in the acquisition, revitalization, and late-lifecycle management of mature, established 'princeps' (original brand) prescription and over-the-counter (OTC) medicines. Laboratoire XO operates as a lean, asset-light platform, outsourcing its manufacturing to a network of contract manufacturing organizations (CMOs) across Europe and the United States. Its diversified portfolio spans key therapeutic areas including cardiology, the central nervous system, pain management, women's health, and oral care, with notable brands such as Loxen, Nimotop, Mantadix, and Barhemsys. Backed by private equity firm Stanley Capital Partners since 2022, the company continues to expand its global footprint through strategic M&A and digital go-to-market strategies.